NCT01403792View on ClinicalTrials.gov

A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

P2G12

A single intravaginal administration of 1ml P2G12/placebo.

Trial Locations (1)

GU2 7XP

Surrey Clinical Research Centre, Guildford

All Listed Sponsors
collaborator

European Commission

OTHER

lead

University of Surrey

OTHER

NCT01403792 - A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects | Biotech Hunter | Biotech Hunter